WCG Wealth Advisors LLC Makes New $8.45 Million Investment in Cencora, Inc. $COR

WCG Wealth Advisors LLC acquired a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,015 shares of the company’s stock, valued at approximately $8,449,000.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after purchasing an additional 221,570 shares during the period. State Street Corp increased its holdings in shares of Cencora by 9.3% in the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares during the period. Geode Capital Management LLC increased its holdings in shares of Cencora by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after purchasing an additional 821,098 shares during the period. Finally, Boston Partners increased its holdings in shares of Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of Cencora stock opened at $264.40 on Thursday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The business has a 50-day moving average price of $294.84 and a 200 day moving average price of $331.59. The firm has a market cap of $51.44 billion, a PE ratio of 20.28, a P/E/G ratio of 1.22 and a beta of 0.59.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the prior year, the firm earned $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its board has approved a stock buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on COR shares. William Blair started coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. increased their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.